Barclays’s Pacira BioSciences PCRX Stock Holding History

Barclays’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,500	Closed	-$113K	–	6384
2019 Q4	$113K	Hold	2,500	–	–	﹤0.01%	5414
2019 Q3	$95K	Buy	+2,500	New	+$99.8K	﹤0.01%	5515
2018 Q2	–	Sell	-291,700	Closed	-$9.09M	–	7201
2018 Q1	$9.09M	Buy	291,700 +266,700	+1,067%	+$9.5M	0.01%	1228
2017 Q4	$1.14M	Sell	25,000 -20,900	-46%	-$828K	﹤0.01%	2989
2017 Q3	$1.72M	Buy	+45,900	New	+$1.85M	﹤0.01%	2495
2017 Q2	–	Sell	-158,800	Closed	-$7.24M	–	6854
2017 Q1	$7.24M	Sell	158,800 -28,000	-15%	-$1.21M	0.01%	1089
2016 Q4	$6.03M	Buy	186,800 +166,300	+811%	+$5.55M	0.01%	1272
2016 Q3	$702K	Hold	20,500	–	–	﹤0.01%	2954
2016 Q2	$691K	Sell	20,500 -44,500	-68%	-$2.19M	﹤0.01%	2926
2016 Q1	$3.38M	Hold	65,000	–	–	0.01%	1481
2015 Q4	$4.94M	Buy	+65,000	New	+$3.68M	0.01%	1325
2015 Q3	–	Sell	-2,500	Closed	-$175K	–	6986
2015 Q2	$175K	Hold	2,500	–	–	﹤0.01%	4231
2015 Q1	$220K	Sell	2,500 -12,700	-84%	-$1.29M	﹤0.01%	4275
2014 Q4	$1.34M	Sell	15,200 -10,800	-42%	-$1.02M	﹤0.01%	2917
2014 Q3	$2.5M	Buy	26,000 +14,500	+126%	+$1.41M	﹤0.01%	2456
2014 Q2	$1.05M	Buy	+11,500	New	+$876K	﹤0.01%	3283

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's PCRX Position: Q1 2026 in Review

Barclays reduced its Pacira BioSciences (PCRX) stake by 19% in Q1 2026, selling an estimated $1.5M and leaving 282,108 shares worth $6.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Barclays first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.3M in Q1 2017. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Barclays held 282,108 shares of Pacira BioSciences worth $6.38M as of Q1 2026.
Barclays sold 67,334 Pacira BioSciences shares in Q1 2026, an estimated $1.5M.
Pacira BioSciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1678 holding.
Barclays first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
Barclays's Pacira BioSciences position peaked at $12.3M in Q1 2017.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.